论文部分内容阅读
本研究旨在阐明临床实践中与溶栓疗法有关的颅内出血的发生率及确定临床预测因素。方法:作者对荷兰61所医院所有用溶栓剂治疗的急性心肌梗塞(AMI)患者,进行检测与溶栓疗法有关的颅内出血患者,选择每1例颅内出血患者与同医院同时期发生AMI并接受溶栓治疗的2例患者作对照,两组病例的临床特征比较包括年龄、低体重(<70kg)、入院前抗凝或抗血小板药物的应用或合用、入院后单独或联用肝素,口服抗凝或抗血小板疗法、入院时高血压(治疗开始前至少两次血压>165/95mmHg或同时升高)、周围血管病(间歇性跛行史或有血管杂音)及吸烟。
This study aimed to elucidate the incidence of intracranial hemorrhage associated with thrombolytic therapy in clinical practice and to determine the clinical predictors. METHODS: The authors examined patients with intracranial hemorrhage associated with thrombolytic therapy for all patients with thrombolytic therapy of acute myocardial infarction (AMI) in 61 hospitals in the Netherlands, who chose to have AMI concurrent with the same hospital for each of the patients with intracranial hemorrhage Two patients undergoing thrombolytic therapy served as controls. The clinical characteristics of the two groups included age, low body weight (<70 kg), application of anticoagulation or antiplatelet drugs prior to admission, or combination of heparin alone or in combination on admission Anticoagulant or antiplatelet therapy, hypertension on admission (blood pressure> 165 / 95mmHg or elevated at least twice before treatment began), peripheral vascular disease (history of intermittent claudication or vascular murmur), and smoking.